Gilead Sciences Inc., the developer of life-changing HIV, hepatitis C and cancer therapies, plans to build a 175,000-square-foot, multi-story research center on its Foster City headquarters campus.
"It's a significant investment," Ganguly said."It is the largest capital investment that we will be making in our master plan in the last four years."in its master plan with Foster City. That long-range document gives the company flexibility to accelerate building projects, yet the new research center still must go through a number of city reviews and isn't planned to open until late 2026.
Gilead has been known as a deep-pocketed buyer of drug programs already in clinical trials, including some of its early HIV drugs, its string of hepatitis C therapies, its cancer cell therapy business and its potential multi-cancer drug Trodelvy, which it received as part of its $21 billion acquisition of Immunomedics Inc. in October 2020.
"A key tenet of the master plan is to create an internal research infrastructure that catalyzes our ambitions in the three therapeutics areas" — virology, inflammation and cancer — Martin said."This new center will do just that by helping further accelerate and scale our ability to create new solutions to serious medical challenges.